Stockreport

Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects [Yahoo! Finance]

Aligos Therapeutics, Inc. - Common stock  (ALGS) 
PDF company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that dosing in the Phase 2a HERALD study of [Read more]